Simplified Chinese
scroll down
24
2019-04
Minhai Biotechnology was honored by the General Union of the Biopharmaceutical Industrial Base.
On the afternoon of April 11, the General Union of the Pharmaceutical Industrial Base convened the 2019 Annual Conference of Grassroots Union Chairpersons in the park. Nearly one hundred union chairpersons and union officials from more than 60 enterprises that have established unions attended, jointly reviewing the union’s work in 2018 and discussing plans for 2019.
23
2019-04
Public Opinion Form for the Environmental Impact Assessment of the Construction Project: 13‑Valent Pneumococcal Conjugate Vaccine Workshop and Acellular Pertussis (Component) Vaccine Bulk‑Drug Substance Workshop, Beijing Minhai Biotechnology Co., Ltd. Date of Completion: Year Month Day Project Name: Construction Project of the 13‑Valent Pneumococcal Conjugate Vaccine Workshop and the Acellular Pertussis (Component) Vaccine Bulk‑Drug Substance Workshop, Beijing Minhai Biotechnology Co., Ltd. I. This page is intended to collect public comments and suggestions related to the environmental impacts of this project and its environmental protection measures. (Note: In accordance with the Measures on Public Participation in Environmental Impact Assessment, opinions or requests concerning land acquisition, relocation, property, employment, or other matters unrelated to the project’s environmental impact assessment are not within the scope of this project.)
11
2019-04
On the morning of April 8, members of the Hermansen family, along with senior executives from DSD Group and HerfoFinans of the Hefu Financial Group, paid a site visit to Beijing Minhai Biotechnology Co., Ltd. Su Rong, Director of the District Science and Technology Commission; Ma Yanzhu, Director of the District Industrial Promotion Center; and Tian Dexiang, Director of the Biopharmaceutical Base Management Committee, accompanied the delegation. Zheng Haifa, General Manager of Minhai Biotechnology, Wu Chengyu, Assistant to the General Manager, Zhang Qian, Manager of the International Cooperation Department, and other relevant leaders extended a warm welcome to the visiting delegation on behalf of Minhai Biotechnology.
29
2019-03
IKSA experts visited Minhai Biotechnology to assess the operation of its quality management system.
From March 18 to 22, 2019, a three-member IKSA expert team visited Minhai to assess the operation of its quality management system. Minhai’s General Manager Zheng Haifa, Executive Deputy General Manager Liu Jiankai, Vice President of Quality Li Xiangqun, Vice President of Production Nie Xiaoqi, and other relevant department heads extended a warm welcome to the IKSA experts.
13
2019-03
In accordance with the requirements of the Measures for Public Participation in Environmental Impact Assessment, the full text of the Environmental Impact Assessment Report for the Minhai Biotechnology International Vaccine Industrial Base (Phase I) Construction Project, together with the Public Participation Statement, is hereby made public. The complete report is attached, and the Public Participation Statement is set out below. 1. Overview The Minhai Biotechnology International Vaccine Industrial Base (Phase I) Construction Project is located within the Xingyi Biopharmaceutical Industrial Base, with the following boundaries: to the north, Simiao Road; to the south, the planned land‑use boundary; to the west, Xiangrui Avenue; and to the east, Tianfu Avenue. The project site covers an area of 90,013.218 m², and the total floor area of Phase I is 149,320 m², of which…
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%